1 Introduction Glioblastoma (GBM) is the most commonly diagnosed malignant tumor in the central nervous system. Prognosis for GBM patients remains poor, with a 2-year survival rate of ∼30% and almost complete mortality [1-3]. Further, the median survival for GBM has only increased 4 months since 2005 [1, 4], highlighting the ongoing need for more innovative and effective therapies.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Anna
Contact Anna, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack